Sensile, Sanofi, and Verily Form Diabetes Dream Team

The collaboration will focus on the commercialization of an “all-in-one” pre-filled insulin patch pump.

There has been a lot of movement in the diabetes space lately – especially with the 78th Scientific Sessions of the American Diabetes Association ending earlier this week.

One of the latest developments in the diabetes space is a “dream team” collaboration with Sensile Medical, Sanofi and Verily (formerly Google Life Sciences) to develop a connected insulin patch pump. Olten, Switzerland-based Sensile Medical develops devices for liquid drug delivery.

The three parties said they will develop and commercialize a new generation of “all-in-one” pre-filled insulin patch pump, primarily to serve people living with type 2 diabetes.

The alliance will use Sanofi's expertise in patient-centered diabetes solutions and insulins; Sensile Medical’s specialty in developing micro-pump technologies for medical use; and Verily’s experience in micro-electronic integration and digital healthcare technology.

“Our goal is to develop a new type of pump technology that is simple to use and appropriate for people with type 2 diabetes, as well as by those with type 1 diabetes who are the primary users of insulin pumps today,” said Derek Brandt, CEO of Sensile Medical in a release.

Verily has heavily relied on partnerships to help it establish its presence in healthcare. MD+DI has chronicled seven key collaborations that have helped build Verily into a healthcare juggernaut. Several of Verily’s partnerships reach far into the diabetes space.

Verily has even formed a joint venture with Paris-based Sanofi in 2016 called Onduo. The Cambridge, MA-based company said its mission is to help people with diabetes live full, healthy lives by developing comprehensive solutions that combine devices, software, medicine, and professional care to enable simple and intelligent disease management.

 

Filed Under
500 characters remaining